Clinical Trial: The efficacy and safety of toripalimab in combination with lenvatinib and TACE for conversion therapy in patients with potentially resectable hepatocellular carcinoma: A prospective, multicenter, single-arm Phase II study (China)

Posted On: 2026-08-24

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The efficacy and safety of toripalimab in combination with lenvatinib and TACE for conversion therapy in patients with potentially resectable hepatocellular carcinoma: A prospective, multicenter, single-arm Phase II study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130619

Registration Time: 2026/08/21

Type: Interventional study

Primary Sponsor: The Affiliated Hospital of Qingdao University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339388

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: The efficacy and safety of toripalimab in combination with lenvatinib and TACE for conversion therapy in patients with potentially resectable hepatocellular carcinoma: A prospective, multicenter, single-arm Phase II study (China)